Document Detail


Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.
MedLine Citation:
PMID:  21466501     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The diversion, misuse, and non-medically supervised use of buprenorphine and buprenorphine/naloxone by opioid users are reviewed. Buprenorphine and buprenorphine/naloxone are used globally as opioid analgesics and in the treatment of opioid dependency. Diversion of buprenorphine and buprenorphine/naloxone represents a complex medical and social issue, and has been widely documented in various geographical regions throughout the world. We first discuss the clinical properties of buprenorphine and its abuse potential. Second, we discuss its diversion and illicit use on an international level, as well as motivations for those activities. Third, we examine the medical risks and benefits of buprenorphine's non-medically supervised use and misuse. These risks and benefits include the effect of buprenorphine's use on HIV risk and the risk of its concomitant use with other medications and drugs of abuse. Finally, we discuss the implications of diversion, misuse, and non-medically supervised use (including potential measures to address issues of diversion); and potential areas for further research.
Authors:
Michael A Yokell; Nickolas D Zaller; Traci C Green; Josiah D Rich
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Current drug abuse reviews     Volume:  4     ISSN:  1874-4745     ISO Abbreviation:  Curr Drug Abuse Rev     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-04-11     Completed Date:  2011-07-25     Revised Date:  2012-05-07    
Medline Journal Info:
Nlm Unique ID:  101468123     Medline TA:  Curr Drug Abuse Rev     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  28-41     Citation Subset:  IM    
Affiliation:
Division of Infectious Diseases, The Miriam Hospital, Providence, RI 02906, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Buprenorphine / adverse effects*,  therapeutic use
HIV Infections / epidemiology,  transmission
Humans
Motivation
Naloxone / adverse effects*,  therapeutic use
Narcotic Antagonists / adverse effects*,  therapeutic use
Narcotics / adverse effects*
Opioid-Related Disorders / economics,  epidemiology,  psychology
Overdose
Risk-Taking
Street Drugs*
Grant Support
ID/Acronym/Agency:
K24 DA022112-01A2/DA/NIDA NIH HHS; K24DA022112/DA/NIDA NIH HHS; P30-AI-42853/AI/NIAID NIH HHS; P30DA013868/DA/NIDA NIH HHS; R21CE001846-01/CE/NCIPC CDC HHS
Chemical
Reg. No./Substance:
0/Narcotic Antagonists; 0/Narcotics; 0/Street Drugs; 465-65-6/Naloxone; 52485-79-7/Buprenorphine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Drug-related decrease in neuropsychological functions of abstinent drug users.
Next Document:  Unemployment and substance use: a review of the literature (1990-2010).